Skip to content
InsiderTrades
SIGMA
Analysis
Recommendations
TOP
Basket
NEW
Terminal
NEW
Companies
Executives
Performance
Blog
GB
EN
GB
EN
Insiders
Trades
Sigma
Companies · Healthcare & Pharma · InsiderTrades Sigma · page 21
Sector
3,940
Healthcare & Pharma
Foresight Acquisition Corp.
Forest Road Acquisition Corp.
Forian Inc.
68m
Forma Therapeutics Holdings, Inc.
Formycon AG
336m
Forte Biosciences, Inc.
899m
Fortress Biotech, Inc.
107m
Forza Innovations Inc
252k
Frans Venker
Frans Venker
359m
Fredun Pharma
14bn
Fredun Pharma
15bn
Frequency Therapeutics, Inc.
Fresenius Medical Care AG
11bn
Fresenius SE & Co. KGaA
24bn
Fulcrum Therapeutics, Inc.
233m
Fulgent Genetics, Inc.
593m
Fusion Pharmaceuticals Inc.
Future Health ESG Corp.
G1 Therapeutics, Inc.
GAROFALO HEALTH CARE
475m
GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A. ACQUISISCE CASA DI CURA CITTA’ DI ROMA / GAROFALO HEALTH CARE S.P.A. ACQUIRES CASA DI CURA CITTA' DI ROMA
470m
GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A.: ASSEMBLEA ORDINARIA E STRAORDINARIA DEGLI AZIONISTI / ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING
470m
GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A.: IL CDA APPROVA IL RESOCONTO INTERMEDIO DI GESTIONE AL 31 MARZO 2026 / BOARD OF DIRECTORS APPROVES INTERIM FINANCIAL REPORT AT MARCH 31, 2026
482m
GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A.: STANDARD ETHICS ALZA IL RATING DI SOSTENIBILITA' / STANDARD ETHICS RAISES SUSTAINABILITY RATING
GAROFALO HEALTH CARE GAROFALO HEALTH CARE S.P.A.: STANDARD ETHICS CONFERMA IL RATING ESG DI BREVE E MEDIO/LUNGO TERMINE / STANDARD ETHICS CONFIRMS SHORT-TERM AND MEDIUM/LONG-TERM ESG RATINGS
GAROFALO HEALTH CARE GHC ACQUISISCE LO STORICO GRUPPO ROMANO DA CUI HA TRATTO LE SUE ORIGINI / GHC ACQUIRES THE HISTORICAL ROMAN GROUP FROM WHICH IT DREW ITS ORIGINS
470m
GAROFALO HEALTH CARE SPA
482m
GBS Inc.
GBS Inc.
GC메디아이
151bn
GDR
7.1m
GENFIT
516m
GENOMED S.A.
GENOWAY
28m
GERON CORP
962m
GLAUKOS Corp
9.1bn
GMR Solutions Inc.
836m
GRAIL, Inc.
3.3bn
GRIFOLS, S.A
6.5bn
GRIFOLS, S.A.
6.2bn
GROUPE TERA
13m
GSK plc
78bn
GSS
83m
GT Biopharma, Inc.
16m
GUERBET
110m
GVS GVS
GVS SPA
802m
GW Pharmaceuticals PLC
Gabather AB
23m
← Previous
Page 21 of 79
Next →